文献速递妇科

子宫癌患者的雌激素替代治疗与非激素药物使用

Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer.
PubMed 文献 · Gynecol Oncol · 2023-12-01

本研究利用MarketScan数据库分析2008至2020年间子宫癌术后患者雌激素替代治疗(ERT)与非激素 menopause 治疗的使用趋势。共纳入19,700例子宫癌患者和185,150例对照。倾向评分平衡后双重差分分析显示,子宫癌患者术后ERT使用较良性病理对照减少,非激素药物使用增加;术后新发ERT使用随时间下降。

要点

  • 子宫癌患者术后ERT使用不常见,且随时间呈下降趋势。
  • 与良性病理对照相比,子宫癌患者术后ERT使用减少,非激素药物使用增加。
  • 18-49岁患者ERT使用的双重差分值为-37.1%(95% CI,-40.5至-33.6%)。

核心结论

  • 子宫癌患者中ERT使用不常见且随时间下降;相反,非激素药物在子宫癌患者中更常用。

研究设计与样本

  • 使用MarketScan数据库识别2008至2020年间18-49岁行子宫切除术加卵巢切除术的患者以及50-75岁行子宫切除术的患者。
  • 共识别19,700例子宫癌患者和185,150例对照。
  • 采用倾向评分平衡后行双重差分分析,比较组间术前与术后ERT及非激素药物使用的变化。
  • 使用Cochran-Armitage趋势检验评估术后ERT使用趋势。

主要发现

  • 18-49岁患者中,子宫癌与良性病理对照术后ERT使用的双重差分为-37.1%(95% CI,-40.5至-33.6%)。
  • 50-75岁患者中,子宫癌与良性病理对照术后ERT使用的双重差分为-10.4%(95% CI,-10.9至-9.9%)。
  • 18-49岁患者中,子宫癌与良性病理对照术后非激素药物使用的双重差分为11.2%(95% CI,7.8至14.7%)。
  • 50-75岁患者中,子宫癌与良性病理对照术后非激素药物使用的双重差分为3.4%(95% CI,2.9至4.0%)。
  • 子宫癌患者术后新发ERT使用随时间下降:18-49岁组P=0.02,50-75岁组P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: As the prognosis for endometrial cancer is excellent, management of the effects of estrogen deprivation has an important influence on quality of life. We examined the trends in the use of estrogen replacement therapy (ERT) and non-hormonal medications among patients with uterine cancer following surgery. METHODS: The MarketScan Database was used to identify patients 18-49 years who underwent hysterectomy plus oophorectomy and those aged 50-75 years who underwent hysterectomy between 2008 and 2020. ERT and non-hormonal treatments of menopause were identified preoperatively and postoperatively. After propensity score balancing, difference-in-differences (DID) analyses were performed to compare the pre-and-postoperative changes in ERT and non-hormonal medication use between groups. The trends in postoperative use of ERT were assessed and tested using Cochran-Armitage trend tests. RESULTS: A total of 19,700 patients with uterine cancer and 185,150 controls were identified. Overall, postoperative ERT use decreased for both age groups and for patients with and without uterine cancer. The DID in ERT use between those with uterine cancer and those with benign pathology after hysterectomy was -37.1% (95% CI, -40.5 to -33.6%) for patients 18-49 years of age and - 10.4% (95% CI, -10.9 to -9.9%) for those 50-75 years. The DID for non-hormonal medication use between those with uterine cancer and those with benign pathology after hysterectomy was 11.2% (95% CI, 7.8 to 14.7%) for younger patients and 3.4% (95% CI, 2.9 to 4.0%) for those 50-75 years. The postoperative new ERT use has been declining over time in patients with uterine cancer in those 18-49 years of age (P = .02) and those 50-75 years of age (P < .001). CONCLUSIONS: The use of ERT is uncommon and has declined over time in patients with uterine cancer. Conversely, non-hormonal medications are more commonly used among patients with uterine cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Suzuki Y, Chen L, Ferris JS, et al. Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer. Gynecol Oncol. 2023. PMID: 38041899. doi:10.1016/j.ygyno.2023.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。